Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi

Özlem Tarçın

TR

Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi

Abstract

Anti-oksidan bir enzim olan paraoksonaz-1(PON1) enzim düzeyi ve aktivitesi, koroner arter hastalığı ile ilişkili olan hipertansiyon, diyabet, hiperlipidemi ve sigara kullanımı ile azalmaktadır. Tüm çalışmalar anjiografik olarak koroner arter hastalığı(KAH) kanıtlanmış olan hastalarda PON1 düzeyinin düştüğünü göstermektedir. Ancak polimorfizm açısından net olarak tek bir polimorfizm ile ilişkisi gösterilememiştir. Bu bilgilerin ışığında PON1 enzim düzeyi, KAH gelişimi açısından belirleyici bir marker olabilir. Ancak bunun klinik olarak kanıtlanması için prospektif ve kontrollü çalışmalara ihtiyaç vardır.

Anahtar Kelimeler: Paraoksonaz-1, Koroner kalp hastalıkları, PON1 polimorfizm

Keywords

-

References

Primo-Parmo SL, Sorenson RC, Teiber J, La Du
BN. The human serum paraoxonase/arylesterase
gene (PON1) is one member of a multigene family.
Genomics 1996;33:498-507. doi:
1006/geno.1996.0225
Mackness MI, Hallam SD, Peard T, Warner S,
Walker CH. The separation of sheep and human
serum “A”-esterase activity into the lipoprotein

fraction by ultracentrifugation. Comp Biochem
Physiol B 1985;82:675-677.
Reddy ST, Wadleigh DJ, Grijalva V, et al. Human
paraoxonase-3 is an HDL-associated enzyme with
biological activity similar to paraoxonase-1 protein
but is not regulated by oxidized lipids. Arterioscler
Thromb Vasc Biol 2001;21:542-547.
Mochizuki H, Scherer SW, Xi T,et al. Human PON2
gene at 7q21.3:cloning, multiple mRNA forms, and
missense polymorphisms in the coding sequence.
Gene 1998;213:149-157. doi: 10.1016/S0378-
(98)00193-0
Costa LG, Vitalone A, Cole TB, et al. Modulation of
paraoxonase (PON1) activity. Biochem Pharmacol
;69: 541-550. doi: 10.1016/j.bcp.22004.08.027
Mueller RF, Hornung S, Furlong CE, Anderson J,
Giblett ER, Motulsky AG. Plasma paraoxonase
polymorphism: a new enzyme assay, population,
family, biochemical and linkage studies. Am J Hum
Genet 1983;35:393-408.
Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter
RJ, Shih DM, et al. Expression of human
paraoxonase (PON1) during development.
Pharmacogenetics 2003;13:1-8. do.:
1097/00008571-200306000-00007
Augustinsson KB, Barr M. Age variation in plasma
arylesterase activity in children. Clin Chim Acta
;8:568-573. doi: 10.1016/0009-8981(63)90106-
-
Ecobichon DJ, Stephens DS. Perinatal
development of human blood esterases. Clin
Pharmacol Ther 1973;14:41-47.
de Roos NM, Schouten EG, Scheek LM, van Tol A,
Katan MB. Replacement of dietary saturated fat
with trans fat reduces serum paraoxonase activity in
healthy men and women. Metabolism
;51:1534-1537. doi: 10.1053/meta.2002.36305
Wallace AJ, Sutherland WHF, Mann JI, Williams
SM. The effect of meals rich in thermally stressed
olive and safflower oils on post-prandial serum
paraoxonase activity in patients with diabetes. Eur J
Clin Nutr 2001;55:951-958.
Deakin SP, James RW. Genetic and enviromental
factors modulating serum concentrations and
activities of the antioxidant enzyme paraoxonase-1.
Clinical Science 2004;107: 435-447. doi:
1042/CS20040187
Mackness MI, Arrol S, Durrington PN. Paraoxonase
prevents accumulation of lipoperoxides in lowdensity
lipoprotein. FEBS Lett. 1991;286(1-2):152-
doi: 10.1016//0014-5793(91)80962-3
Gordon T, Castelli WP, Hjortland MC, Kannel WB,
Dawber TR. High density lipoprotein as a protective
factor against coronary heart disease. The
Framingham Study. Am J Med 1977;62:707-714.
doi: 10.1016/00029343(77)90874-9
Kaysen GA. Potential restoration of HDL function
with apolipoprotein A-I mimetic peptide in end-stage
renal disease. Kidney Int 2009;76(4):359-61. doi:
1038/ki.2009.205
Mackness B, Hine D, Liu Y, et al. Paraoxonase-1
inhibits oxidized LDL-induced MCP-1 production by
endothelial cells. Biochem Biophys Res Commun
;318:680-683. doi: 10.1016/j.bbrc.2004.04.056
Ferretti G, Bacchetti T, Marchionni C,et al. Effect of
glycation of high density lipoproteins on their
physiochemical properties and on paraoxonase
activity. Acta Diabetol 2001;38:163-169. doi:
1007/s592-001-8074-z
Gofman JW, Young W, Tandy R. Ischemic heart
disease, atherosclerosis, and longevity. Circulation
;34:679-697.
Rozenberg O, Rosenblat M, Coelman R, et al.
Paraoxonase (PON1) deficiency is associated with
increased macrophage oxidative stres: studies in
PON1-knockout mice. Free Radic Biol Med
;34:774-784. doi: 10.1016/S0891-
(02)01429-6
Navab M, Hama-Levy S, Van Lenten BJ, Fonarow
GC, Carlinez CJ, Castellani LW. Mildly oxidised
LDL induces an increased apolipoprotein
J/paraoxonase ratio. J Clin Invest 1997;99:2005-
doi: 10.1172/JCI119369
Singh S, Venkatesh S, Verma JS, Verma M,
Lellama CO, Goel RC. Paraoxonase(PON1) activity
in North west Indian Punjabis with coronary artery
disease. Indian J Med Res 2007;125:783-787.
Jayakumari N, Thejaseebai G. High prevalence of
low serum paraoxonase1 in subjects with coronary
artery disease. J Clin Biochem Nutr 2009;45(3):278-
doi: 10.3164/jcbn.08-255
Kabaroğlu C, Mutaf I, Boydak B, et al. Association
between serum paraoxonase activity and oxidative
stress in acute coronary syndromes. Acta Cardiol
;59:606-611.
Aviram M, Rosenbalt M. Paraoxonases and
cardiovascular diseases: pharmacological and
nutritional influences. Curr Opin Lipidol
;16:393-399.
Suehiro T, Nakanchi Y, Yammamoto M, Arii K, Itoh
H, Hamashige N, et al. Paraoxonase gene
polymorphism in Japanese subjects with coronary
heart disease. Br J Pharmacol 1996;57:69-73. doi:
1016/S0167-5273(96)02779-9
Antikainen M, Mutomaki S, Syvanne M, Pahlman R,
Tanvanainen E, Jauhianen M, et al. The Gln Arg
polymorphism of human paraoxonase gene
(HUMPONA) is not associated with the risk of
coronary artery disease in Finns. J Clin Invest
;98:883-885.
Mukamal KJ, Pai JK, Jensen MK, Rimm EB.
Paraoxonase 1 polymorphisms and risk of
myocardial infarction in women and men. Circ J
;73(7):1302-1307. doi: 10.1253/circj.CJ-08-
-
Rios DL, D’Onofrio LO, Cerqueira CC, Bonfim-Silva
R, Carvalho HG, Santos-Filho A, et al. Paraoxonase
gene polymorphisms in angiographically
assessed coronary artery disease: evidence for
gender interaction among Brazilians. Clin Chem
Lab Med 2007;45:874-878. doi:
1515/CCLM.2007.136
Sanghera DK, Saha N, Aston CE, Kamboh MI.
Genetic polymorphism of paraoxonase and the risk
of coronary heart disease. Arterioscler Thromb
Vasc Biol 1997;17:1067-1073.
Ruiz J, Blanche H, James RW, Garin MC, Vaisse C,
CharpentierG, Cohen N, Morabia A, Passa P,
Froguel P. Gln-Arg 192 polymorphism of
Ö. TARÇIN
Paraoksonaz-1 ve koroner kalp hastalığı
Marmara Medical Journal 2011; 24 (1):59-63
-
paraoxonase and coronary heart disease in type 2
diabetes. Lancet 1995;346(8979):869-872.
doi:10.1016/S0140-6736(95)92709-3
Kaman D, İlhan N, Metin K, Akbulut M, Üstündağ B.
A preliminary study of human paraoxonase and
PON1 L/M55-PON1 Q/R192 polymorphisms in
Turkish patients with coronary artery disease. Cell
Biochem Funct 2009;27:88-92. doi:
1002/cbf.1539
Özkök E, Aydın M, Babalık E, Özbek Z, İnce N,
Kara İ. Combined impact of matrix
metalloproteinase-3 and paraoxonase 1 55/192
gene variants on coronary artery disease in Turkish
Patients. Med Sci Monit 2008;14(19):536-542.
Aynacıoğlu AS, Kepekçi Y. The human
paraoxonase Gln-Arg 192(Q/R) polymorphism in
Turkish patients with coronary artery disease. Int J
Cardiol 2000;12:33-37. doi: 10.1016.S0167-
(00)00242-4
Wheeler JG, Keavney BD, Watkins H, Collins R,
Danesh J. Four paraoxonase gene polymorphism in
cases of coronary heart diseases and 12786
controls: meta-analysis of 43 studies. Lancet
;363(9410):689-695. doi: 10.1016/S0140-
(04)15642-0
Tartan Z, Orhan G, Kaşıkçıoğlu H, Uyarel H, Ünal
S, Özer N, Özay B, Çiloğlu F, Çam N. The role of
paraoxonase (PON) enzyme in the extent and
severity of the coronary artery disease in type-2
diabetic patients. Heart Vessels 2007;22(3):158-
doi: 10.1007/s00380-0060957-6
Ferretti G, Bacchetti T, Busni D, et al. Protective
effect of paraoxonase activity in high-density
lipoproteins against erythrocyte membranes
peroxidation: a comparison between healthy
subjects and type 1 diabetic patients. J Clin
Endocrinol Metab 2004;89:2957-2962.
Karabina SA, Lehner AN, Franke E, Parthasara S,
Santanam N. Oxidative inactivation of paraoxonaseimplications
in diabetes mellitus and
atherosclerosis. Biochim Biophys Acta
;1725(2):213-221. doi:
1016/j.bbagen.2005.07.005
Flekac M, Skrha J, Zidkova K, Lacinova Z,
Hilgertova J. Paraoxonase 1 gene polymorphisms
and enzyme activities in diabetes mellitus. Physiol
Res 2008;57(5):717-26.
Chen X, Wu Y, Liu L, Su Y, Peng Y, Jiang L, Liu X,
Huang D. Relationship between high density
lipoprotein antioxidant activity and carotid intima
media thickness in patients with essential
hypertension. Clin Exp Hypertens 2010;32:13-20.
Yıldız A, Gür M, Demirbağ R, Yılmaz R, Akyol S,
Aslan M, Erel O. Paraoxonase and arylesterase
activities in untreated dipper and non-dipper
hypertensive patients. Clin Biochem 2008;41(10-
:779-784. doi:
1016/j.clinbiochem.2008.02.010
Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N,
Minami N, et al. Relation between nocturnal decline
in blood pressure and mortality. The Ohasama
Study. Am J Hypertens 1997;10:1201-1207. doi:
1016/S0895-7061(97)00274-4
Metohi H, Ohkubo T, Kikuya M, Asayama K, Obara
T, Hashimoto J, et al. Prognostic significance for
stroke of a morning pressor surge and a nocturnal
blood pressure decline:the Ohasama study.
Hypertension 2006;47:149-154. doi:
1161/01.HYP.0000198541.12640.0f
Connelly PW, Zinman B, Maguire GF,
Mamakeesick M, Haris SB, Hegele RA, Retnakaren
R, hanley AJ. Association of the novel
cardiovascular risk factors paraoxonase 1 and
cystatin C in type 2 diabetes. J Lipid res
;50(6):1216-1222. doi: 10.1194/jlr.P80070-
JLR200
Ribas V, Sanchez-Quesada JL, Anton R, Camacho
M, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J,
Blanco-Vaca F. Human apolipoprotein A-II
enrichement displaces paraoxonase from HDL and
impairs its antioxidant properties. Circ Res
;95:789-797. doi:
1161/01.RES0000146031.94850.5f
Paragh G, Seres I, Harangi M, Balogh Z, Illyes L, et
al. The effect of micronised fenofibrate on
paraoxonase activity in patients with coronary heart
disease. Diabetes Metab 2003;29:613-618. doi:
1016/S1262-3636(07)70077-0
Beltowski J, Wòjcicka G, Mydlarczyk M, Jamroz A.
The effect of peroxisome proliferator-activated
receptors (PPAR) alpha agonist, fenofibrate, on lipid
peroxidation, total antioxidant capacity, and
plasma paraoxonase 1(PON1) activity. J Physiol
Pharmacol 2002;53:463-475.
Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk Gy,
Paragh Gy. Gemfibrozil increases paraoxonase
activity in type 2 diabetic patients. A new hypothesis
of the beneficial action of fibrates? Diabetes Metab
;27:604-610.
Durrington PN, Mackness MI, Bhatnagar D, Julier
K, Prais H, Arrol S, Morgan J, Wood GNI. Effects of
two different fibric acid derivatives on lipoproteins,
cholesterol ester transfer, fibrinogen, plasminogen
activator inhibitor and paraoxonase activity in type
IIb hyperlipoproteinemia. Atherosclerosis
;138:217-225. doi:
1161/01.ATV.0000027414.34728.1F
Senti M, Tomas M, Anglada R, Elosua R, Marrugat
J, Covas MI, et al. Inter-relationship of smoking,
paraoxonase activity, and leisure time physical
activity:a population based study. Eur J Int Med
;14:178-184. doi: 10.10167S0953-
(03)00041-4
Mouhamed DH, Ezzaher A, Araoud M, Neffati F,
Douki W, Najjar MF. Paraoxonase 1(PON1) activity
and lipid parameters in Tunusian smokers. Ann Biol
Clin 2010;68;143-147. doi: 10.1684/abc.2010.0418
James RW, Leviev I, Righetti A. Smoking is
associated with reduced serum paraoxonase
activity and concentration in patients with coronary
artery disease. Circulation 2000;101:2252-2257.
Nishio E, Watanabe Y. Cigarette smoke extracts
inhibits plasma paraoxonase activity by modification
of the enzyme’s free thiols. Biochem Biophys Res
Comm 1997;236:289-293. doi:
1006/bbrc.1997.6961

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Özlem Tarçın

Publication Date

April 21, 2015

Submission Date

April 21, 2015

Acceptance Date

-

Published in Issue

Year 2011 Volume: 24 Number: 1

IZ

https://izlik.org/JA98PM26UG

Cite

RIS / Bibtex

APA

Tarçın, Ö. (2015). Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi. Marmara Medical Journal, 24(1), 59-63. https://izlik.org/JA98PM26UG

AMA

1.Tarçın Ö. Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi. Marmara Med J. 2015;24(1):59-63. https://izlik.org/JA98PM26UG

Chicago

Tarçın, Özlem. 2015. “Paraoksonaz-1 Enzimi Ve Koroner Kalp Hastalıkları Ile İlişkisi”. Marmara Medical Journal 24 (1): 59-63. https://izlik.org/JA98PM26UG.

EndNote

Tarçın Ö (August 1, 2015) Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi. Marmara Medical Journal 24 1 59–63.

IEEE

[1]Ö. Tarçın, “Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi”, Marmara Med J, vol. 24, no. 1, pp. 59–63, Aug. 2015, [Online]. Available: https://izlik.org/JA98PM26UG

ISNAD

Tarçın, Özlem. “Paraoksonaz-1 Enzimi Ve Koroner Kalp Hastalıkları Ile İlişkisi”. Marmara Medical Journal 24/1 (August 1, 2015): 59-63. https://izlik.org/JA98PM26UG.

JAMA

1.Tarçın Ö. Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi. Marmara Med J. 2015;24:59–63.

MLA

Tarçın, Özlem. “Paraoksonaz-1 Enzimi Ve Koroner Kalp Hastalıkları Ile İlişkisi”. Marmara Medical Journal, vol. 24, no. 1, Aug. 2015, pp. 59-63, https://izlik.org/JA98PM26UG.

Vancouver

1.Özlem Tarçın. Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi. Marmara Med J [Internet]. 2015 Aug. 1;24(1):59-63. Available from: https://izlik.org/JA98PM26UG